Diffuse mucosal damage in the large intestine associated with Irinotecan (CPT-11)

Digestive Diseases and Sciences

Volumn 43, Issue 12, 1998, Pages 2649-2651

  Van Huyen, Jean Paul Duong ^b   Bloch, Francis ^b   Attar, Alain ^b   Levoir, Damien ^b   Kreft, Carmen ^b   Molina, Thierry ^b   Bruneval, Patrick ^a  

^a HÔPITAL BROUSSAIS   (France)

^b NONE

Author keywords

Colitis; Colorectal cancer; CPT 11; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FLUOROURACIL; IRINOTECAN;

ADULT; ARTICLE; ATROPHY; CANCER CHEMOTHERAPY; CASE REPORT; COLON BIOPSY; COLON MUCOSA; DIARRHEA; DRUG INDUCED DISEASE; EPITHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE INTESTINE; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLON; COLONIC NEOPLASMS; FATAL OUTCOME; HUMANS; INTESTINAL MUCOSA; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 0032410846     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026647110060     Document Type: Article

References (14)

1. Hsiang YH, Hertzberg R, Hecht S, Lin LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
2. Rougier P, Bugat R, Douillard JY, Culine S, Sue E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Gamen G, Namer M, Conroy T, Negrier S, Merrouehe Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
3. Rothenherg ML: Topoisomerase I inhibitors: Review and update. Ann Oncol 8:837-855, 1947
4. Bleiberg H, Cvitkovic E: Characterisation and clinical management of CPT-11 (irinotecan)-induccd adverse events: the european perspective. Eur J Cancer 32A (suppl):S18-S23, 1996
5. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A: Relashionship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jnp J Cancer Res 84:697-702, 1993
6. Ikuno N, Soda H, Wanatabe M, Oka M: Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 87:1876-1883, 1995
7. Lee FD: Importance of apoptosis in the histopathology of drug related lesions in the large intestine. J Clin Pathol 46:118-122, 1993
8. Levin RJ: Anatomical and functional changes of the small intestine induced by 5-Huorouracil. J Physiol (London) 197:73P-74P, 1968
9. Milles SS, Muggia AL, Spiro HM: Colonic histologic changes induced by 5-fluorouracil. Gastroenterology 43:391-399, 1962
10. Baker JL, Gosland MP, Herrington JD, Record KE: Cytomegalovirus colitis after 5-fluorouracil and interferon-alpha therapy. Pharmacotherapy 14:246-249, 1994
11. Trevisani F, Simoncini M, Alampi G, Bernardi M: Colitis associated to chemotherapy with 5-Fluorouracil. Hepato-Gastroenterology 44:710-712, 1997
12. Brown JW: Toxic megacolon associated with loperamide therapy. JAMA 241:501-502, 1979
13. Guffroy M, Hodge T: Irinitecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 88:1240-1241, 1996
14. Guichard S, Hennebelle I, Bugat R, Canal P: Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (Irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55:667-676, 1998